Loading…
IRIDEX Corporation is projected to rise to $0.9966 by 2027, a +12% move from its current price of $0.8908. IRIX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/25/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 26 | $0.87 | $0.8906 | $0.9117 | -0.02% |
| Jul 27 | $0.8614 | $0.8904 | $0.9203 | -0.05% |
| Jul 28 | $0.8548 | $0.8901 | $0.927 | -0.07% |
| Jul 29 | $0.8492 | $0.8899 | $0.9326 | -0.10% |
| Jul 30 | $0.8443 | $0.8897 | $0.9375 | -0.12% |
| Jul 31 | $0.8399 | $0.8895 | $0.942 | -0.15% |
| Aug 1 | $0.8359 | $0.8893 | $0.9461 | -0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8359 | $0.8893 | $0.9461 | -0.17% |
| Week 2 | $0.8133 | $0.8878 | $0.969 | -0.34% |
| Week 3 | $0.7961 | $0.8863 | $0.9866 | -0.51% |
| Week 4 | $0.7817 | $0.8847 | $1.00 | -0.68% |
| Week 5 | $0.769 | $0.8832 | $1.01 | -0.85% |
| Week 6 | $0.7576 | $0.8817 | $1.03 | -1.02% |
| Week 7 | $0.7472 | $0.8802 | $1.04 | -1.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
IRIDEX Corporation is a healthcare company focused on ophthalmic medical technology. It provides therapeutic laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. Its product lines include Cyclo G6 laser system for glaucoma, IQ 532 and IQ 577 laser systems for retinal disorders, and the OcuLight family of laser photocoagulation systems used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
IRIDEX serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through a direct and independent sales force in the United States, as well as through independent distributors internationally. The company operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. It was incorporated in 1989 and is headquartered in Mountain View, California.
It was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995.
IRIDEX Corporation (IRIX) is a healthcare stock with a current price of $0.951 and a market cap of $16.55M, ranked 4866 by market capitalization. The near-term price path shows a flat-to-moderate trajectory, with 2026 projected min $0.95, avg $0.951, max $1.17 and a 0% ROI, indicating limited upside in the immediate horizon.
From 2027 onward, the forecast envisions a rising price trajectory with 2027 avg $1.09, 2028 avg $1.30, 2029 avg $1.43, and 2030 avg $1.58, accompanied by bullish sentiment. The longer-range view strengthens further, with 2035 avg $2.20, 2040 avg $2.67, and a 2050 avg of $5.44, while the predicted max climbs to $10.00 and ROI to 472.1%.
Overall, the outlook suggests substantial upside over the multi-year horizon, albeit with the usual uncertainty inherent in forward-looking estimates.
A major floor 16.9% below — a decisive break under it would weaken the trend.
Support has flipped 3.3% overhead — reclaiming it would be bullish.
The nearest ceiling, 33.6% above — a clean break opens room to run.
A major ceiling 51.5% above — clearing it would confirm fresh momentum.
Key IRIX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IRIX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.924 | Sell | $0.9368 | Sell |
| MA 10 | $0.986 | Sell | $0.9772 | Sell |
| MA 20 | $1.06 | Sell | $1.03 | Sell |
| MA 50 | $1.08 | Sell | $1.08 | Sell |
| MA 100 | $1.12 | Sell | $1.11 | Sell |
| MA 200 | $1.14 | Sell | $1.16 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 22.46 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -116.30 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -17.86 | Sell |
| Bollinger %B (20,2) | 0.12 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.39 | Sell |
| Awesome (5,34) | -0.17 | Sell |
| Ultimate (7,14,28) | 4.50 | Buy |
| Momentum (10) | -0.20 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 0.89 | Sell |
| ADX (14) | 28.52 | Sell |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is NEUTRAL. RSI14 sits at 20, indicating subdued momentum, while the 50-day simple moving average is $1.09 and the 200-day simple moving average is $1.15. This alignment shows prices currently trading around the short- and medium-term moving averages without a clear bullish or bearish tilt.
Immediate support is at $0.95 and resistance at $1.19. The 30-day price range spans from $0.7964 up to $1.14, underscoring limited near-term volatility within a narrow band around the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.8908 | $0.8908 | $1.09 | 0% | Neutral | |
| $0.8047 | $0.9966 | $1.30 | +12% | Neutral | |
| $0.9244 | $1.17 | $1.58 | +32% | Bullish | |
| $0.9974 | $1.29 | $1.78 | +45% | Bullish | |
| $1.07 | $1.40 | $1.98 | +58% | Bullish | |
| $1.03 | $1.38 | $1.98 | +55% | Bullish | |
| $1.03 | $1.40 | $2.05 | +57% | Bullish | |
| $1.10 | $1.52 | $2.26 | +70% | Bullish | |
| $1.20 | $1.68 | $2.53 | +88% | Bullish | |
| $1.38 | $1.94 | $2.96 | +118% | Bullish | |
| $1.59 | $2.37 | $3.82 | +166% | Bullish | |
| $2.91 | $4.75 | $8.31 | +433% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.8908 | $0.8908 | $1.05 | +0.00% |
| August 2026 | $0.7514 | $0.8807 | $1.06 | -1.14% |
| September 2026 | $0.7384 | $0.8712 | $1.06 | -1.07% |
| October 2026 | $0.7566 | $0.8976 | $1.10 | +3.03% |
| November 2026 | $0.7609 | $0.9068 | $1.12 | +1.03% |
| December 2026 | $0.7353 | $0.8801 | $1.09 | -2.95% |
Click any year to see its month-by-month IRIX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The IRIX price prediction for 2026 points to an average of $0.8908 (low $0.8908, high $1.09) — a potential gain of 0% on today's $0.8908. A consolidation phase looks the most probable path here.
In 2027, IRIX is projected to trade between $0.8047 and $1.30, averaging $0.9966 — a potential gain of +12% from today's $0.8908. That is up +12% on the projected 2026 average. Price action looks broadly range-bound.
IRIDEX Corporation's 2028 outlook centres on $1.17, within a $0.9244 to $1.58 range. That is up +18% on the projected 2027 average. That marks a +32% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, IRIX could reach as high as $1.78, with a base case around $1.29 and support toward $0.9974 — roughly +45% from $0.8908. Momentum favours further upside here.
Expect IRIX to range from $1.07 to $1.98 through 2030. The $1.40 average target implies a +58% move from current prices. That is up +9% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The IRIX price prediction for 2031 points to an average of $1.38 (low $1.03, high $1.98) — a potential gain of +55% on today's $0.8908. Momentum favours further upside here.
In 2032, IRIX is projected to trade between $1.03 and $2.05, averaging $1.40 — a potential gain of +57% from today's $0.8908. That is up +1% on the projected 2031 average. Buyers look set to stay in control over this stretch.
IRIDEX Corporation's 2033 outlook centres on $1.52, within a $1.10 to $2.26 range. That is up +8% on the projected 2032 average. That marks a +70% change versus current levels. Momentum favours further upside here.
By 2034, IRIX could reach as high as $2.53, with a base case around $1.68 and support toward $1.20 — roughly +88% from $0.8908. Buyers look set to stay in control over this stretch.
Expect IRIX to range from $1.38 to $2.96 through 2035. The $1.94 average target implies a +118% move from current prices. That is up +16% on the projected 2034 average. Momentum favours further upside here.
The IRIX price prediction for 2040 points to an average of $2.37 (low $1.59, high $3.82) — a potential gain of +166% on today's $0.8908. Buyers look set to stay in control over this stretch.
In 2050, IRIX is projected to trade between $2.91 and $8.31, averaging $4.75 — a potential gain of +433% from today's $0.8908. That is up +100% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in IRIX today (≈ 1,122.586439 IRIX) could be worth
$5,329.54
+$4,329.54 (+433%) by 2050 · US Dollar
Based on the average projected IRIX price of $4.75 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IRIXwould be worth at today's price.
$1,000 invested in IRIX on Jul 23, 2025 (≈ 709.219875 IRIX) would be worth
$631.77
-$368.23 (-36.8%) today · 0.63× · US Dollar
Based on a IRIX entry price of $1.41 vs. today's $0.8908.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.95 | $937.68 | -6.2% |
| 1 month ago | $1.18 | $754.92 | -24.5% |
| 3 months ago | $1.06 | $840.38 | -16.0% |
| 6 months ago | $1.52 | $586.05 | -41.4% |
| 1 year ago | $1.41 | $631.77 | -36.8% |
| All time (5.0y) ago | $6.55 | $136 | -86.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IRIX forecast.
Our base-case forecast reaches $1.80 around 2035.
Implied market cap at $1.80: $31.33M
The multi-year forecast paints a bullish arc for IRIDEX, with the average price rising from $1.58 in 2030 to $2.20 by 2035, $2.67 by 2040, and ultimately $5.44 by 2050. Across those years, ROI progresses from 65.9% in 2030 to 131.3% in 2035, 180.7% in 2040, and 472.1% in 2050, reflecting a strong long-run appreciation potential.
The sequence of years shows steady improvement, including 2027 avg $1.09 (ROI 14.8%), 2028 avg $1.30 (36.9%), 2029 avg $1.43 (50.3%), and 2033 avg $1.71 (80%). These points illustrate a persistent uptrend over the mid-to-late 2020s and into the 2030s, with the peak-long horizon reaching a substantially higher level than today. As with all such forecasts, the figures are estimates and carry uncertainty; actual results may differ.
Tap a question to reveal the answer.
The forecast for 2030 shows min $1.17, avg $1.58, max $2.29 with ROI 65.9% and bullish sentiment.
The long-run forecast indicates a bullish trajectory, with 2050 avg $5.44 and ROI 472.1%, alongside earlier years showing rising averages (e.g., 2027 avg $1.09, ROI 14.8%; 2028 avg $1.30, ROI 36.9%). Current price is $0.951 with a market cap of $16.55M and a neutral near-term RSI, so outcomes depend on future performance and market conditions.
Yes. The forecast maximum for 2050 is $10.00, with an average of $5.44 and ROI of 472.1%.
RSI14 is 20, indicating relatively weak near-term momentum.
The current price is $0.951, the market cap is $16.55M, and the stock is ranked 4866. IRIDEX operates in the Healthcare sector.
IRIDEX Corporation Community Discussion
0Share your IRIDEX Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.